Novus Therapeutics, Inc. (NVUS) formed multiple bottom with $3.66 target or 8.00% below today’s $3.98 share price. Novus Therapeutics, Inc. (NVUS) has $28.20 million valuation. The stock decreased 1.97% or $0.08 during the last trading session, reaching $3.98. About 6,754 shares traded. Novus Therapeutics, Inc. (NASDAQ:NVUS) has 0.00% since January 3, 2017 and is . It has underperformed by 16.70% the S&P500.
GROGENESIS INCORPORATED (OTCMKTS:GROG) had a decrease of 88.89% in short interest. GROG’s SI was 100 shares in January as released by FINRA. Its down 88.89% from 900 shares previously. It closed at $0.1505 lastly. It is down 0.00% since January 3, 2017 and is . It has underperformed by 16.70% the S&P500.
GroGenesis, Inc., an agricultural services company, makes and sells plant growth surfactants. The company has market cap of $14.95 million. The firm offers AgraBurst, a nano-surfactant nutrient emulsifier. It currently has negative earnings. It serves farmers, fertilizer manufacturers, and commercial lawn and turf companies.